ZO-FAST Study of the Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Early Breast Cancer


ZO-FAST Study of the Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Early Breast Cancer
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

deBoer R et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The ZO-FAST study 5-year final follow-up. San Antonio Breast Cancer Symposium 2010;Abstract P5-11-01.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.